Skip to main content
CURIS INC logo

CURIS INC — Investor Relations & Filings

Ticker · CRIS ISIN · US2312693094 LEI · 5299000YO6CX4WMFVX06 US Manufacturing
Open in API
Filings indexed 1,023 across all filing types
Latest filing 2026-06-05 Proxy Solicitation & In…
Country US United States of America
Listing US CRIS

About CURIS INC

https://www.curis.com/

Curis, Inc. is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. The company's clinical pipeline is led by emavusertib (CA-4948), a small molecule inhibitor of the IRAK4 kinase, being investigated for hematologic malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and non-Hodgkin lymphoma (NHL). Additional clinical-stage programs include fimepinostat, a dual inhibitor of HDAC and PI3K for MYC-altered cancers, and CA-170, an oral antagonist targeting the VISTA and PDL1 immune checkpoints. The company's portfolio also includes Erivedge, a Hedgehog pathway inhibitor approved for basal cell carcinoma and licensed to Genentech.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2026-06-05 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a U.S. SEC Form 8-K current report dated May 19, 2026, detailing both an amendment to the company’s certificate of incorporation to increase authorized shares and, critically, the voting results from the Annual Meeting on five proposals. It contains tabulated vote tallies for each proposal. This aligns precisely with the “Declaration of Voting Results & Voting Rights Announcements” category, which covers official results from shareholder votes at any general meeting.
2026-05-22 English
10-Q - CURIS INC (0001108205) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
8-K - CURIS INC (0001108205) (Filer)
Regulatory Filings Classification · 90% confidence The document is a SEC Form 8-K “Current Report” under the Securities Exchange Act, furnishing a press release as an exhibit. It does not contain substantive financial statements itself but serves as a regulatory filing to report results of operations. It’s not the earnings release itself nor a full quarterly report (10-Q) but a compliance filing. Thus it falls under the “Regulatory Filings” category.
2026-05-12 English
8-K - CURIS INC (0001108205) (Filer)
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 27, 2026, by Curis, Inc. The key content is about receiving a Delist Determination Letter from Nasdaq due to the company's stock price being below the minimum bid price requirement for continued listing. The document discusses the delisting process, the company's intent to appeal, and the potential consequences. There are no financial statements or detailed financial data presented. The primary purpose is to announce the delisting notice and related procedural information. According to the filing definitions, this matches the description of a Delisting Announcement (DLST). The document length is 6223 characters, which is sufficient to contain substantive information rather than a mere announcement of a report. Therefore, the correct classification is DLST with high confidence.
2026-05-01 English
ARS - CURIS INC (0001108205) (Filer)
Annual Report
2026-04-21 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.